使用清除率和脑渗透研究作为筛选,四氢异喹啉3被鉴定为大鼠中清除率较低的铅(CLb 20 ml / min / kg)。将7-CF 3 SO 2 O-取代基引入四氢异喹啉中,然后用3-吲哚基丙烯酰胺基取代3-联苯酰胺基基团,得到31,其具有高的D3受体亲和力(pKi 8.4)和比D2受体高150倍的选择性。
Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors
申请人:Fleck Roman Wolfgang
公开号:US20090227588A1
公开(公告)日:2009-09-10
Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.
本发明涉及对可溶性环氧水解酶(sEH)活性的化合物,其组成物和使用和制备它们的方法。
ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
申请人:Yamagishi Tatsuya
公开号:US20120232052A1
公开(公告)日:2012-09-13
The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar
1
is phenyl; Ar
2
is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO
2
—, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.
Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor
作者:Nigel E. Austin、Kim Y. Avenell、Izzy Boyfield、Clive L. Branch、Martyn C. Coldwell、Michael S. Hadley、Phillip Jeffrey、Amana Johns、Christopher N. Johnson、David J. Nash、Graham J. Riley、Stephen A. Smith、Rachel C. Stacey、Geoffrey Stemp、Kevin M. Thewlis、Antonio K.K. Vong
DOI:10.1016/s0960-894x(98)00699-4
日期:1999.1
7-CF3SO2O- substituent into the tetrahydroisoquinoline, followed by replacement of the biphenylamido group of 3 by a 3-indolylpropenamido group gave 31, having high D3 receptoraffinity (pKi 8.4) and 150 fold selectivity over the D2 receptor.
使用清除率和脑渗透研究作为筛选,四氢异喹啉3被鉴定为大鼠中清除率较低的铅(CLb 20 ml / min / kg)。将7-CF 3 SO 2 O-取代基引入四氢异喹啉中,然后用3-吲哚基丙烯酰胺基取代3-联苯酰胺基基团,得到31,其具有高的D3受体亲和力(pKi 8.4)和比D2受体高150倍的选择性。